Related references
Note: Only part of the references are listed.Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses
Julia Li et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection
Eleanor C. Semmes et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
1048. Double-Blind, Randomized, Placebo-Controlled Phase 2b Multicenter Trial of V160, a Replication-Defective Human Cytomegalovirus (CMV) Vaccine
Rituparna Das et al.
Open Forum Infectious Diseases (2021)
Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity
Hsuan-Yuan Wang et al.
VIRUSES-BASEL (2021)
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial
Leike Li et al.
NPJ VACCINES (2021)
Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step
Xiaohua Ye et al.
PLOS PATHOGENS (2020)
Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection
Matthew L. Goodwin et al.
VIROLOGY (2020)
Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans
Jennifer A. Jenks et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Antibody responses to viral infections: a structural perspective across three different enveloped viruses
Charles D. Murin et al.
NATURE MICROBIOLOGY (2019)
Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects
Stuart P. Adler et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
A proof of concept for structure-based vaccine design targeting RSV in humans
Michelle C. Crank et al.
SCIENCE (2019)
Human Cytomegalovirus Cell Tropism and Host Cell Receptors
Giuseppe Gerna et al.
VACCINES (2019)
Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees
Cody S. Nelson et al.
JOURNAL OF VIROLOGY (2019)
Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model
Sarah Valencia et al.
VACCINE (2019)
Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia
Ilona Baraniak et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections
Sallie R. Permar et al.
JOURNAL OF VIROLOGY (2018)
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies
Ilona Baraniak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells
Xiaohong Cui et al.
JOURNAL OF VIROLOGY (2017)
Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants
Kristy M. Bialas et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway
Thomas J. Gardner et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2016)
A replication-defective human cytomegalovirus vaccine for prevention of congenital infection
Dai Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
David I. Bernstein et al.
VACCINE (2016)
Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding
Maria Panico et al.
SCIENTIFIC REPORTS (2016)
Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody
Sumana Chandramouli et al.
NATURE COMMUNICATIONS (2015)
A High-Affinity Native Human Antibody Neutralizes Human Cytomegalovirus Infection of Diverse Cell Types
Lawrence M. Kauvar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection
Daniele Lilleri et al.
PLOS ONE (2013)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Paul D. Griffiths et al.
LANCET (2011)
International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation
Camille N. Kotton et al.
TRANSPLANTATION (2010)
Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant
Robert F. Pass
JOURNAL OF CLINICAL VIROLOGY (2009)
Polyfunctional Cytomegalovirus-Specific CD4+and pp65 CD8+T Cells Protect Against High-Level Replication After Liver Transplantation
G. Nebbia et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection
Giuseppe Gerna et al.
JOURNAL OF GENERAL VIROLOGY (2008)
Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection
Aileen Kenneson et al.
REVIEWS IN MEDICAL VIROLOGY (2007)
Variation and infectivity neutralization in influenza
Marcel Knossow et al.
IMMUNOLOGY (2006)
Share Paper
